

## Title (en)

CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITIS

## Title (de)

KORTIKOSTEROIDHALTIGE IM MUND ZERFALLENDE TABLETTENZUSAMMENSETZUNGEN FÜR EOSINOPHILE ÖSOPHAGITIS

## Title (fr)

COMPOSITIONS POUR COMPRIMÉS À DÉLITEMENT ORAL CONTENANT DES CORTICOSTÉROÏDES UTILISÉES POUR TRAITER L'ESOPHAGITE À ÉOSINOPHILES

## Publication

**EP 3041476 B2 20230125 (EN)**

## Application

**EP 14842811 A 20140905**

## Priority

- US 201361874450 P 20130906
- US 2014054203 W 20140905

## Abstract (en)

[origin: WO2015035114A1] The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

## IPC 8 full level

**A61K 9/20** (2006.01); **A61K 9/00** (2006.01); **A61K 31/56** (2006.01); **A61P 1/00** (2006.01); **A61P 1/04** (2006.01); **A61P 29/00** (2006.01)

## CPC (source: EP IL KR RU US)

**A61J 3/10** (2013.01 - IL US); **A61K 9/0056** (2013.01 - EP IL KR US); **A61K 9/16** (2013.01 - IL RU); **A61K 9/20** (2013.01 - IL RU); **A61K 9/2009** (2013.01 - EP IL US); **A61K 9/2018** (2013.01 - EP IL US); **A61K 9/2027** (2013.01 - EP IL US); **A61K 9/2054** (2013.01 - EP IL KR US); **A61K 9/2081** (2013.01 - IL US); **A61K 9/2095** (2013.01 - EP IL US); **A61K 31/56** (2013.01 - IL KR RU US); **A61K 31/573** (2013.01 - IL); **A61K 31/58** (2013.01 - KR); **A61K 45/06** (2013.01 - IL US); **A61K 47/02** (2013.01 - IL); **A61K 47/26** (2013.01 - IL); **A61K 47/30** (2013.01 - IL); **A61K 47/32** (2013.01 - IL); **A61K 47/36** (2013.01 - IL); **A61K 47/38** (2013.01 - IL); **A61P 1/00** (2018.01 - EP IL RU); **A61P 1/04** (2018.01 - EP IL KR); **A61P 29/00** (2018.01 - EP IL); **B29C 43/003** (2013.01 - IL US); **B29C 43/006** (2013.01 - IL US)

## Citation (opposition)

Opponent :

- WO 2010144865 A2 20101216 - MERITAGE PHARMA INC [US], et al
- WO 2009086046 A1 20090709 - EURAND INC [US], et al

## Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

## DOCDB simple family (publication)

**WO 2015035114 A1 20150312**; AU 2014315110 A1 20160421; AU 2014315110 B2 20191212; BR 112016004844 A2 20170801; BR 112016004844 B1 20220426; CA 2923055 A1 20150312; CA 2923055 C 20200915; CA 3089453 A1 20150312; CL 2016000510 A1 20160909; CN 105722513 A 20160629; CN 105722513 B 20211022; CY 1122626 T1 20210312; DK 3041476 T3 20200127; EP 3041476 A1 20160713; EP 3041476 A4 20170426; EP 3041476 B1 20191106; EP 3041476 B2 20230125; EP 3659587 A1 20200603; ES 2764849 T3 20200604; ES 2764849 T5 20230531; HK 1225974 A1 20170922; HR P20200015 T1 20200320; HU E048533 T2 20200728; IL 244419 A0 20160421; IL 244419 B 20220401; IL 291562 A 20220501; IL 291562 B1 20231001; IL 291562 B2 20240201; IL 305908 A 20231101; JP 2016529314 A 20160923; JP 6514702 B2 20190515; KR 102341165 B1 20211220; KR 102609926 B1 20231205; KR 20160058829 A 20160525; KR 20210158858 A 20211231; KR 20230169421 A 20231215; LT 3041476 T 20200410; MX 2016002866 A 20161026; MY 179870 A 20201118; NZ 718371 A 20210326; PL 3041476 T3 20200430; PT 3041476 T 20200120; RS 59803 B1 20200228; RU 2016112259 A 20171011; RU 2016112259 A3 20180516; RU 2019100068 A 20190322; RU 2019100068 A3 20220419; RU 2678695 C2 20190131; SA 516370678 B1 20200308; SG 10201901677Y A 20190328; SG 11201601663X A 20160428; SI 3041476 T1 20200331; UA 119969 C2 20190910; US 10471071 B2 20191112; US 11166961 B2 20211109; US 11260061 B2 20220301; US 2016206627 A1 20160721; US 2020016171 A1 20200116; US 2021205328 A1 20210708; US 2022110945 A1 20220414; WO 2015034678 A2 20150312; WO 2015034678 A3 20150730; ZA 201702906 B 20181219

## DOCDB simple family (application)

**US 2014054203 W 20140905**; AU 2014315110 A 20140905; BR 112016004844 A 20140905; CA 2923055 A 20140905; CA 3089453 A 20140905; CL 2016000510 A 20160304; CN 201480055152 A 20140905; CY 201100018 T 20200108; DK 14842811 T 20140905; EP 14842811 A 20140905; EP 19207287 A 20140905; ES 14842811 T 20140905; HK 16114345 A 20161216; HR P20200015 T 20200107; HU E14842811 A 20140905; IL 24441916 A 20160303; IL 29156222 A 20220321; IL 30590823 A 20230913; JP 2016540402 A 20140905; KR 20167008886 A 20140905; KR 20217041119 A 20140905; KR 20237041178 A 20140905; LT 14842811 T 20140905; MX 2016002866 A 20140905; MY P12016000419 A 20140905; NZ 71837114 A 20140905; PL 14842811 T 20140905; PT 14842811 T 20140905; RS P20200010 A 20140905; RU 2016112259 A 20140905; RU 2019100068 A 20140905; SA 516370678 A 20160305; SG 10201901677Y A 20140905; SG 11201601663X A 20140905; SI 201431448 T 20140905; UA A201603351 A 20140905; US 2014052073 W 20140821; US 201414917125 A 20140905; US 201916578568 A 20190923; US 202117211119 A 20210324; US 202117559068 A 20211222; ZA 201702906 A 20170425